Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

David Seftel; David R. Boulware

doi:10.1093/ofid/ofab050

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

David Seftel, David R. Boulware

Medicine - Infectious Disease and International Medicine

Research output: Contribution to journal › Article › peer-review

123 Scopus citations

Abstract

We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.

Original language	English (US)
Article number	ofab050
Journal	Open Forum Infectious Diseases
Volume	8
Issue number	2
DOIs	https://doi.org/10.1093/ofid/ofab050
State	Published - Feb 1 2021

Bibliographical note

Publisher Copyright:
© 2021 The Author(s).

Keywords

COVID-19
SARS-COV-2
cohort
coronavirus
fluvoxamine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1093/ofid/ofab050

Find It

Find It at U of M Libraries

Cite this

@article{6301690fc1154d4086244f5bf7c0327a,

title = "Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19",

abstract = "We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.",

keywords = "COVID-19, SARS-COV-2, cohort, coronavirus, fluvoxamine",

author = "David Seftel and Boulware, {David R.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s).",

year = "2021",

month = feb,

day = "1",

doi = "10.1093/ofid/ofab050",

language = "English (US)",

volume = "8",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

AU - Seftel, David

AU - Boulware, David R.

PY - 2021/2/1

Y1 - 2021/2/1

N2 - We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.

AB - We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.

KW - COVID-19

KW - SARS-COV-2

KW - cohort

KW - coronavirus

KW - fluvoxamine

UR - http://www.scopus.com/inward/record.url?scp=85104850130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104850130&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofab050

DO - 10.1093/ofid/ofab050

M3 - Article

C2 - 33623808

AN - SCOPUS:85104850130

SN - 2328-8957

VL - 8

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 2

M1 - ofab050

ER -

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this